Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.
about
Identification of Maturation-Specific Proteins by Single-Cell Proteomics of Human Oocytes.High expression of S100P is associated with unfavorable prognosis and tumor progression in patients with epithelial ovarian cancerOverexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cellsSerum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancerDiagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies.The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review.Prediction of therapy response in ovarian cancer: Where are we now?Evaluating the clinical significances of serum HE4 with CA125 in peritoneal tuberculosis and epithelial ovarian cancer.Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.Naphthazarin suppresses cell proliferation and induces apoptosis in human colorectal cancer cells via the B-cell lymphoma 2/B-cell associated X protein signaling pathway.Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer.YKL-40 in the diagnosis, prediction of prognosis, and platinum sensitivity in serous epithelial ovarian cancer
P2860
Q34527950-89781DCA-C2B4-4E5C-9E8C-B0DB15F4B19BQ36057106-D5BFC921-6D3D-4678-8ECB-9CF05C33873EQ36545468-CD6EA403-E724-463B-A6A8-B61F23E337BBQ36907257-FBAD4C56-1323-4CDA-91C1-A92B16FE6C9FQ37291762-447D8F54-8A0E-4638-B7FA-A8A3E202ABC6Q38393888-6DBCC781-DD9F-41D3-9300-AB2634ED14FAQ38653169-9743B9ED-941D-4B3B-9CC9-3B01BF4ED480Q39263260-4786704C-61A2-41AC-89F5-A4195C639F5CQ40212320-13785784-2F87-49E2-A5E6-97C841F57F24Q40581487-434B08C7-9F60-403E-854E-06AE4596E0A5Q41389424-0C796E22-9C0A-46EE-9AC4-32E8656203B5Q52627963-7189BAAA-D441-4549-9339-D767E04A7A91Q54993659-70597551-3566-43B4-9230-4D3A135AB08BQ58767748-D0CF42DF-6C20-4E89-A54E-64ECC146FC83
P2860
Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Serum HE4, CA125, YKL-40, bcl- ...... hemotherapy in ovarian cancer.
@ast
Serum HE4, CA125, YKL-40, bcl- ...... hemotherapy in ovarian cancer.
@en
type
label
Serum HE4, CA125, YKL-40, bcl- ...... hemotherapy in ovarian cancer.
@ast
Serum HE4, CA125, YKL-40, bcl- ...... hemotherapy in ovarian cancer.
@en
prefLabel
Serum HE4, CA125, YKL-40, bcl- ...... hemotherapy in ovarian cancer.
@ast
Serum HE4, CA125, YKL-40, bcl- ...... hemotherapy in ovarian cancer.
@en
P2093
P2860
P356
P1476
Serum HE4, CA125, YKL-40, bcl- ...... chemotherapy in ovarian cancer
@en
P2093
Agnieszka Monika Sompolska-Rzechuła
Aleksandra Izabela Tołoczko-Grabarek
Aneta Alicja Cymbaluk-Płoska
Izabella Anna Rzepka-Górska
P2860
P2888
P356
10.1186/1757-2215-7-62
P577
2014-06-10T00:00:00Z
P5875
P6179
1041173485